You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameObinutuzumab
Accession NumberDB08935
TypeBiotech
GroupsApproved
DescriptionObinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
Protein structureDb08935
Related Articles
Protein chemical formulaC6512H10060N1712O2020S44
Protein average weight146100.0 Da
SequencesNot Available
Synonyms
Afutuzumab
External Identifiers
  • GA-101
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GazyvaInjection, solution, concentrate1000 mg/40mLIntravenousGenentech, Inc.2013-11-01Not applicableUs
GazyvaSolution25 mgIntravenousHoffmann La Roche Limited2014-11-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIO43472U9X8
CAS number949142-50-1
Pharmacology
IndicationObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
Structured Indications
PharmacodynamicsObinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.
Mechanism of actionIn contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
TargetKindPharmacological actionActionsOrganismUniProt ID
B-lymphocyte antigen CD20Proteinyes
antibody
HumanP11836 details
Related Articles
AbsorptionObinutuzumab is administered intravenously, so its absorption is 100%.
Volume of distribution

Obinutuzumab has a volume of distribution of about 3.8 L.

Protein bindingObinutuzumab does not bind to plasma proteins.
Metabolism

Obinutuzumab is not metabolized by the liver.

Route of eliminationThe route of elimination of obinutuzumab was not indicated (FDA label).
Half lifeThe half life of obinutuzumab is 28.4 days.
Clearance

The clearance of obinutuzumab is 0.09L/day.

ToxicityThe most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obinutuzumab.Approved
AcebutololAcebutolol may increase the hypotensive activities of Obinutuzumab.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Obinutuzumab.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Obinutuzumab.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Obinutuzumab.Approved
AliskirenAliskiren may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Obinutuzumab.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Obinutuzumab.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Obinutuzumab is combined with ALT-110.Investigational
AmbrisentanAmbrisentan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Obinutuzumab.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Obinutuzumab.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Obinutuzumab.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Obinutuzumab.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Obinutuzumab.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Obinutuzumab.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Obinutuzumab.Approved
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Obinutuzumab.Investigational
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Obinutuzumab.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Obinutuzumab.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Obinutuzumab.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Obinutuzumab.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Obinutuzumab.Approved
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Obinutuzumab.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Obinutuzumab.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Obinutuzumab.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Obinutuzumab.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Obinutuzumab.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Obinutuzumab.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Obinutuzumab.Experimental
BarbitalBarbital may increase the hypotensive activities of Obinutuzumab.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Obinutuzumab.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Obinutuzumab.Investigational
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Obinutuzumab.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belimumab.Approved
BenazeprilBenazepril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Obinutuzumab.Approved
BepridilBepridil may increase the hypotensive activities of Obinutuzumab.Approved, Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Obinutuzumab.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Obinutuzumab.Approved
BethanidineBethanidine may increase the hypotensive activities of Obinutuzumab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Obinutuzumab.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Obinutuzumab.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.Approved, Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Obinutuzumab.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Obinutuzumab.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Obinutuzumab.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Obinutuzumab.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Obinutuzumab.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Obinutuzumab.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.Approved
CandesartanCandesartan may increase the hypotensive activities of Obinutuzumab.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Obinutuzumab.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Obinutuzumab.Approved
CaptoprilCaptopril may increase the hypotensive activities of Obinutuzumab.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Obinutuzumab.Approved
CarteololCarteolol may increase the hypotensive activities of Obinutuzumab.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
CDX-110The risk or severity of adverse effects can be increased when Obinutuzumab is combined with CDX-110.Investigational
CeliprololCeliprolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Obinutuzumab.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Obinutuzumab.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Obinutuzumab.Approved
CilazaprilCilazapril may increase the hypotensive activities of Obinutuzumab.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Obinutuzumab.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Obinutuzumab.Approved
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Obinutuzumab.Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Obinutuzumab.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Obinutuzumab.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Obinutuzumab.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Obinutuzumab.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Obinutuzumab.Approved, Nutraceutical
ClozapineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Obinutuzumab.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Obinutuzumab.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Obinutuzumab.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Obinutuzumab.Approved
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.Approved
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab.Approved
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Obinutuzumab.Approved, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Obinutuzumab.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Obinutuzumab.Approved
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Obinutuzumab.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Obinutuzumab.Approved
DeserpidineDeserpidine may increase the hypotensive activities of Obinutuzumab.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Obinutuzumab.Approved
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Obinutuzumab.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Obinutuzumab.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Obinutuzumab.Approved, Vet Approved
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Obinutuzumab.Approved, Vet Approved
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Obinutuzumab.Approved
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Obinutuzumab.Approved
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Obinutuzumab.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Obinutuzumab.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Obinutuzumab.Approved
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Obinutuzumab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Obinutuzumab.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Obinutuzumab.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Obinutuzumab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Obinutuzumab.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Obinutuzumab.Approved
DuloxetineObinutuzumab may increase the orthostatic hypotensive activities of Duloxetine.Approved
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Obinutuzumab.Approved, Vet Approved
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Obinutuzumab.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Obinutuzumab.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Obinutuzumab.Approved
EnalaprilEnalapril may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Obinutuzumab.Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Obinutuzumab.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Obinutuzumab.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Obinutuzumab.Approved
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Obinutuzumab.Investigational
EpoprostenolEpoprostenol may increase the hypotensive activities of Obinutuzumab.Approved
EprosartanEprosartan may increase the hypotensive activities of Obinutuzumab.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Obinutuzumab.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Obinutuzumab.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Obinutuzumab.Withdrawn
FelodipineFelodipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Obinutuzumab.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Obinutuzumab.Approved
FingolimodObinutuzumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluindioneThe risk or severity of adverse effects can be increased when Fluindione is combined with Obinutuzumab.Investigational
FondaparinuxThe risk or severity of adverse effects can be increased when Fondaparinux is combined with Obinutuzumab.Investigational
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Obinutuzumab.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Obinutuzumab.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Obinutuzumab.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with G17DT.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Obinutuzumab.Investigational
GI-5005The risk or severity of adverse effects can be increased when Obinutuzumab is combined with GI-5005.Investigational
GuanabenzGuanabenz may increase the hypotensive activities of Obinutuzumab.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Obinutuzumab.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Obinutuzumab.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Obinutuzumab.Approved, Vet Approved
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Obinutuzumab.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Obinutuzumab.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Obinutuzumab.Approved
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Obinutuzumab.Experimental
HydralazineHydralazine may increase the hypotensive activities of Obinutuzumab.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Obinutuzumab.Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Obinutuzumab.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obinutuzumab.Approved, Nutraceutical
idraparinuxThe risk or severity of adverse effects can be increased when idraparinux is combined with Obinutuzumab.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Obinutuzumab.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Obinutuzumab.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Obinutuzumab.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab.Approved
IndapamideIndapamide may increase the hypotensive activities of Obinutuzumab.Approved
IndenololIndenolol may increase the hypotensive activities of Obinutuzumab.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Obinutuzumab.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Obinutuzumab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Obinutuzumab is combined with INGN 225.Investigational
IrbesartanIrbesartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Obinutuzumab.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Obinutuzumab.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Obinutuzumab.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Obinutuzumab.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Obinutuzumab.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Obinutuzumab.Approved
KetanserinKetanserin may increase the hypotensive activities of Obinutuzumab.Investigational
LabetalolLabetalol may increase the hypotensive activities of Obinutuzumab.Approved
LacidipineLacidipine may increase the hypotensive activities of Obinutuzumab.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Leflunomide.Approved, Investigational
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Obinutuzumab.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Obinutuzumab.Approved
LevodopaObinutuzumab may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Obinutuzumab.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Obinutuzumab.Approved
MacitentanMacitentan may increase the hypotensive activities of Obinutuzumab.Approved
ManidipineManidipine may increase the hypotensive activities of Obinutuzumab.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Obinutuzumab.Approved, Investigational
MecamylamineMecamylamine may increase the hypotensive activities of Obinutuzumab.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Obinutuzumab.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Obinutuzumab.Approved
MethohexitalMethohexital may increase the hypotensive activities of Obinutuzumab.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Obinutuzumab.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Obinutuzumab.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Obinutuzumab.Approved
MetipranololMetipranolol may increase the hypotensive activities of Obinutuzumab.Approved
MetolazoneMetolazone may increase the hypotensive activities of Obinutuzumab.Approved
MetoprololMetoprolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
MetyrosineMetyrosine may increase the hypotensive activities of Obinutuzumab.Approved
MibefradilMibefradil may increase the hypotensive activities of Obinutuzumab.Withdrawn
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Obinutuzumab.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Obinutuzumab.Approved
MoexiprilMoexipril may increase the hypotensive activities of Obinutuzumab.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Obinutuzumab.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Obinutuzumab.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Obinutuzumab.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Obinutuzumab.Approved
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Obinutuzumab.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Obinutuzumab.Investigational
NaftopidilNaftopidil may increase the hypotensive activities of Obinutuzumab.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Obinutuzumab.Investigational
NebivololNebivolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Obinutuzumab.Approved, Investigational
NicardipineNicardipine may increase the hypotensive activities of Obinutuzumab.Approved
NicorandilNicorandil may increase the hypotensive activities of Obinutuzumab.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Obinutuzumab.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Obinutuzumab.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Obinutuzumab.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Obinutuzumab.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Obinutuzumab.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Obinutuzumab.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Obinutuzumab.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Obinutuzumab.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Obinutuzumab.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Obinutuzumab.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Obinutuzumab.Investigational
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Obinutuzumab.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Obinutuzumab.Approved
OxprenololOxprenolol may increase the hypotensive activities of Obinutuzumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Obinutuzumab.Approved
PargylinePargyline may increase the hypotensive activities of Obinutuzumab.Approved
PenbutololPenbutolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Obinutuzumab.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Obinutuzumab.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Obinutuzumab.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Obinutuzumab.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Phenelzine.Approved
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Obinutuzumab.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Obinutuzumab.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Obinutuzumab.Approved
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Obinutuzumab.Approved
PhentolaminePhentolamine may increase the hypotensive activities of Obinutuzumab.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Obinutuzumab.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Obinutuzumab.Withdrawn
PindololPindolol may increase the hypotensive activities of Obinutuzumab.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pipamperone.Approved
PolythiazidePolythiazide may increase the hypotensive activities of Obinutuzumab.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pramipexole.Approved, Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Obinutuzumab.Approved
PrazosinPrazosin may increase the hypotensive activities of Obinutuzumab.Approved
PrimidonePrimidone may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Obinutuzumab.Approved
Protein S humanThe risk or severity of adverse effects can be increased when Protein S human is combined with Obinutuzumab.Approved
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Obinutuzumab.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Obinutuzumab.Approved
QuinaprilQuinapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Obinutuzumab.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Obinutuzumab.Investigational
RamiprilRamipril may increase the hypotensive activities of Obinutuzumab.Approved
RasagilineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Obinutuzumab.Approved
RescinnamineRescinnamine may increase the hypotensive activities of Obinutuzumab.Approved
ReserpineReserpine may increase the hypotensive activities of Obinutuzumab.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.Experimental, Investigational
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Obinutuzumab.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Obinutuzumab.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Obinutuzumab.Investigational
RiociguatRiociguat may increase the hypotensive activities of Obinutuzumab.Approved
RisperidoneObinutuzumab may increase the hypotensive activities of Risperidone.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Obinutuzumab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sacubitril.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Obinutuzumab.Experimental
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Obinutuzumab.Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Obinutuzumab.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Obinutuzumab.Approved, Vet Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Obinutuzumab.Approved
SitaxentanSitaxentan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Obinutuzumab.Approved
SpiraprilSpirapril may increase the hypotensive activities of Obinutuzumab.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Obinutuzumab.Approved
SRP 299The risk or severity of adverse effects can be increased when Obinutuzumab is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Obinutuzumab.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil.Approved, Investigational
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Obinutuzumab.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Obinutuzumab.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tamsulosin.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Obinutuzumab.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Obinutuzumab.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Obinutuzumab.Investigational
TG4010The risk or severity of adverse effects can be increased when Obinutuzumab is combined with TG4010.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Thioridazine.Approved
TiboloneTibolone may increase the hypotensive activities of Obinutuzumab.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Obinutuzumab.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Obinutuzumab.Withdrawn
TimololTimolol may increase the hypotensive activities of Obinutuzumab.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Obinutuzumab.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Obinutuzumab.Approved
TofacitinibObinutuzumab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tolcapone.Approved, Withdrawn
TorasemideTorasemide may increase the hypotensive activities of Obinutuzumab.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Obinutuzumab.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tranylcypromine.Approved
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Obinutuzumab.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Obinutuzumab.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Obinutuzumab.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Obinutuzumab.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Obinutuzumab.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Obinutuzumab.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Obinutuzumab.Approved
UnoprostoneUnoprostone may increase the hypotensive activities of Obinutuzumab.Approved
ValsartanValsartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Obinutuzumab.Approved
VinpocetineVinpocetine may increase the hypotensive activities of Obinutuzumab.Investigational
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Obinutuzumab.Approved
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Obinutuzumab.Approved
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Obinutuzumab.Approved, Investigational, Withdrawn
XylometazolineXylometazoline may increase the hypotensive activities of Obinutuzumab.Approved
Ym150The risk or severity of adverse effects can be increased when Ym150 is combined with Obinutuzumab.Investigational
Food Interactions
  • Echinacea: diminished therapeutic effect of immunosuppressants
References
Synthesis Reference

Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96.

General ReferencesNot Available
External Links
ATC CodesL01XC15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (484 KB)
MSDSNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous1000 mg/40mL
SolutionIntravenous25 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
water solubilityWater solubleNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Mhc class ii protein complex binding
Specific Function:
This protein may be involved in the regulation of B-cell activation and proliferation.
Gene Name:
MS4A1
Uniprot ID:
P11836
Molecular Weight:
33076.99 Da
References
  1. Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96. [PubMed:19513948 ]
Comments
comments powered by Disqus
Drug created on January 05, 2014 13:42 / Updated on August 17, 2016 12:24